Archives of Medical Research
Volume 41, Issue 4 , Pages 281-287 , May 2010

Effect of the DTwP Haemophilus influenzae b Conjugate Vaccination in Mexico (1999–2007)

  • Patricia Gómez de León Cruces

      Affiliations

    • Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional Autónoma de México, México D.F., México
    • Corresponding Author InformationAddress reprint requests to: Dra. Patricia Gómez de León, Cruces, Facultad de Medicina, UNAM, Edificio de Investigación 3er. piso, México, D.F. 04510, México. Phone & FAX: (+52) (55) 5623-2249
    • ,
  • Javier Díaz García

      Affiliations

    • Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional Autónoma de México, México D.F., México
    • ,
  • Jose Ignacio Santos

      Affiliations

    • Departamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, México D.F., México

Received 24 February 2010 ,Accepted 24 May 2010.

References 

  1. Centers for Disease Control . Progress toward elimination of Haemophilus influenzae b disease among infants and children–United States, 1987–1995. MMWR. 1996;45:901–906
  2. Forleo-Neto E, Oliveira CF, Maluf EM, et al. Decreased point prevalence of Haemophilus influenzae type b (Hi b) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hi b polyribosilribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoid-pertussis vaccine. J Infect Dis. 1999;180:1153–1158
  3. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302–317
  4. Trotter CL, McVernon J, Ramsay ME, et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine. 2008;26:4434–4445
  5. Morris SK, Moss WJ, Halsey N. Type b conjugate vaccine use and efectiveness. Lancet Infect Dis. 2008;8:435–443
  6. World Health Organization. http://www.who.int/immunization_monitoring/burden/Pneumo_hib_estimates/en/index1.html (accessed on Feb. 10, 2010)
  7. Cabrera R, Gómez de León P. Prevención de la meningoencefalitis por H. Influenzae del serotipo b y Neisseria meningitidis. In:  Escobar-Gutiérrez A,  Valdespino JL,  Sepúlveda J editor. Vacunas, Ciencia y Salud. 1st ed. México, D.F.: Secretaría de Salud; 1992;p. 259–377
  8. Gómez de León P, Cabrera R. Vacunas contra Haemophilus influenzae b: Presente, pasado y futuro. Salud Publica Mex. 1992;34:274–285
  9. Gómez de León P, Molinari JL, Cabrera R, et al. Serum response to outer membrane proteins of Haemophilus influenzae type b in Mexican children with or without evidence of invasive disease. Immunol Infect Dis. 1995;5:238–243
  10. Gómez de León P, Díaz-García FJ, Arredondo JL, et al. Anticapsular polysaccharide IgG concentrations in Mexican children formerly immunized with Haemophilus influenzae b PRP-T vaccine. Hum Vaccin. 2007;3:187–191
  11. Gómez de León P, Díaz-García FJ, Villaseñor A, et al. Immunoglobulin G avidities in Mexican infants after primary immunization with three doses of polyribosylribitol phosphate-tetanus toxoid Haemophilus influenzae type b vaccine. Clin Vaccine Immunol. 2008;15:1024–1027
  12. Franco-Paredes C, Lammoglia L, Hernandez I, et al. Epidemiology and outcomes of bacterial. meningitis in Mexican children: 10 year experience (1993–2003). Int J Infect Dis. 2008;12:380–386
  13. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology. 2004;113:163–174
  14. Barbour ML, Mayon-White RT, Coles C, et al. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis. 1995;171:93–98
  15. Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae b. Emerg Infect Dis. 1996;2:176–182
  16. Murphy TV, Pastor P, Medlye R, et al. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr. 1993;122:517–523
  17. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b in children immunized with a Hi b conjugate vaccine. J Infect Dis. 1991;122:517–523
  18. Leino T, Takala T, Auranen K, et al. Indirect protection obtained by Haemophilus influenzae type b vaccination: analysis in a structured population model. Epidemiol Infect. 2004;132:959–966
  19. Hammitt LL, Block S, Hennessy TE, et al. Outbreak of invasive Haemophilus influenzae serotype a disease. Pediatr Infect Dis J. 2005;24:453–456
  20. Kapogiannis BG, Satola S, Keyserling HL, et al. Invasive infections with Haemophilus influenzae serotype a containing an IS1016-Bex A partial deletion: possible association with virulence. Clin Infect Dis. 2005;41:e97–e103
  21. Urwin G, Krohn JA, Deaver-Robinson K, et al. Invasive disease due to Haemophilus influenzae serotype f: clinical and epidemiologic characteristics in the H. influenzae serotype b vaccine era. The Haemophilus influenzae Study Group. Clin Infect Dis. 1996;22:1069–1076
  22. Jin Z, Romero-Steiner S, Carlone GM, et al. Haemophilus influenzae type a infection and its prevention. Infect Immun. 2007;75:2650–2654
  23. Gomez De Leon P, Santos JI, Caballero J, et al. Genomic variability of Haemophilus influenzae isolated from Mexican children determined by using enterobacterial repetitive intergenic consensus sequences and PCR. J Clin Microbiol. 2000;38:2504–2511
  24. Gomez De Leon P. Distribución de las secuencias del consenso intergénico repetitivo enterobacteriano entre cepas de Haemophilus influenzae aisladas de casos de enfermedad y de una población de niños vacunados (Ph.D. thesis). Ciudad de México (D.F.): Facultad de Ciencias-UNAM; 2001;
  25. Sosa-Iglesias EG, Anaya-Medina A, Portillo-Gomez L, et al. Biotypes and serotypes of Haemophilus influenzae of clinical isolates from Mexican children. Arch Med Res. 1998;29:133–136
  26. Villaseñor-Sierra A, Ávila-Figueroa C, Santos-Preciado JI. Impacto de las infecciones por Haemophilus influenzae en niños Mexicanos. Bol Med Hosp Infant Mex. 1993;50:415–421
  27. Campos J, Hernando M, Román F, Pérez-Vázquez M, et al. Analysis of invasive Haemophilus influenzae infections after extensive vaccination against Haemophilus influenzae type b. J Clin Microbiol. 2004;42:524–529
  28. de Almeida AE, de Filippis I, de Abreu AO, et al. Ocurrence of Haemophilus influenzae strains in three Brazilian states since the introduction of a conjugate Haemophilus influenzae type b vaccine. Braz J Med Biol Res. 2005;38:777–781
  29. Tsang RSW, Mubareka S, Sill ML, et al. Invasive Haemophilus influenzae in Manitoba, Canada, in the postvaccination era. J Clin Microbiol. 2006;44:1530–1535
  30. Schouls LM, van der Ende A, van de Pol I, et al. Increase in genetic diversity of Haemophilus influenzae serotype b (Hi b) strains after introduction of Hi b vaccination in The Netherlands. J Clin Microbiol. 2005;43:2741–2749
  31. Campos J, Aracil B, Román F, et al. Molecular epidemiology of Haemophilus influenzae type b isolated from children with clinical cases of conjugate vaccine failures. J Clin Microbiol. 2003;41:3915–3918
  32. Bruce KD, Jordens JZ. Characterization of noncapsulate Haemophilus influenzae by whole-cell polypeptide profiles, restriction endonuclease analysis, and rRNA gene restriction patterns. J Clin Microbiol. 1991;29:291–296
  33. Smith-Vaughan HC, Sriprakash KS, Mathews JD, et al. Amplification and restriction endonuclease digestion of a large fragment of genes coding for rRNA as a rapid method for discrimination of closely related pathogenic bacteria. J Clin Microbiol. 1997;35:1646–1647
  34. Selander RK, Beltran P, Smith NH, et al. Evolutionary genetic relationships of clones of Salmonella serovars that cause human typhoid and other enteric fevers. Infect Immun. 1990;58:2262–2275
  35. Meats E, Feil EJ, Stringer S, et al. Characterization of encapsulated and noncapsulated Haemophilus influenzae and determination of phylogenetic relationships by multilocus sequence typing. J Clin Microbiol. 2003;41:1623–1636
  36. Hulton CS, Higgins CF, Sharp PM. ERIC sequences: a novel family of repetitive elements in the genomes of Escherichia coli, Salmonella typhimurium and other enterobacteria. Mol Microbiol. 1991;5:825–834
  37. Lupski JR, Weinstock GM. Short, interspersed repetitive DNA sequences in prokaryotic genomes. J Bacteriol. 1992;174:4525–4529
  38. Phipps DC, West J, Eby R, et al. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods. 1990;135:121–128
  39. Fernández J, Balter S, Feriz J, et al. Randomized trial of the immunogenicity of fractional dose-regimens of PRP-T Haemophilus influenzae type b conjugate vaccine. Am J Trop Med Hyg. 2000;62:485–490
  40. Käyhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100
  41. Austrian R. Pneumococcal polysaccharide vaccines. Rev Infect Dis. 1989;11(Suppl 3):S598–S612
  42. Clarke P, Powell PJ, Goldblatt D, et al. Effect of a fourth Haemophilus influenzae type b immunisation in preterm infants who received dexamethasone for chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2003;88:58–61
  43. Mäkelä PH, Käyhty H, Leino T, et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine. 2003;22:287–292
  44. Trotter CL, McVernon J, Andrews NJ, et al. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet. 2003;361:1523–1524
  45. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365–367
  46. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis. 1998;177:1112–1115
  47. Romero-Steiner S, Holder PF, Gomez de Leon P, et al. Avidity determinations for Haemophilus influenzae type b anti-polyribosylribitol phosphate antibodies. Clin Diagn Lab Immunol. 2005;12:1029–1035
  48. Goldblatt D, Richmond P, Millard E, et al. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus and pertussis vaccine combination. J Infect Dis. 1999;180:538–541
  49. Pichichero ME, Voloshen T, Zajac D, et al. Avidity maturation of antibody to Haemophilus influenzae type b (Hi b) after immunization with diphtheria-tetanus–acellular pertussis–Hi b–hepatitis B combined vaccine in infants. J Infect Dis. 1999;180:1390–1393
  50. Gilsdorf JR, Marrs CF, Foxman B. Haemophilus influenzae: genetic variability and natural selection to identify virulence factors. Infect Immun. 2004;72:2457–2461
  51. Bottero D, Gaillard ME, Fingermann M, et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol. 2007;14:1490–1498
  52. Obaro SK, Adegbola RA, Banya WA, et al. Carriage of pneumococci after pneumococcal vaccination. Lancet. 1996;348:271–272
  53. Dabernat H, Pélissier R, Faucon G, et al. Genotyping of type b Haemophilus influenzae strains, comparison of strains collected before and during vaccine availability. Med Mal Infect. 2005;35:205–212
  54. Rijkers GT, Vermeer-de Bondt PE, Spanjaard L, et al. Return of Haemophilus influenzae type b infections. Lancet. 2003;361:1563–1564
  55. Ulanova M, Tsang RWS. Invasive Haemophilus influenzae disease: changing epidemiology and host-parasite interactions in the 21st century. Infect Genet Evol. 2009;9:594–605
  56. Gessner BD, Adegbola RA. The impact of vaccines on pneumonia: key lessons from Haemophilus influenzae type b conjugate vaccines. Vaccine. 2008;26(suppl):B3–B8
  57. Cruces P, Donoso A, Camacho J, et al. Infecciones invasoras por Haemophilus influenzae tipo b después de la incorporación de la vacuna conjugada al Programa Ampliado de Inmunizaciones en Chile. Rev Chil Infect. 2006;23:50–54
  58. Nascimento-Carvalho CM, de Andrade AL. Haemophilus influenzae type b vaccination: long-term protection. J Pediatr (Rio J). 2006;82(suppl):S109–S114
  59. Booy R, Haworth EA, Ali KA, et al. Immunogenicity of routine vaccination against diphtheria, tetanus and Haemophilus influenzae type b in Asian infants born in the United Kingdom. Arch Dis Child. 2005;90:589–591
  60. Capeding MR, Nohynek H, Käyhty H, et al. Antibody responses of three Haemophilus influenzae type b conjugate vaccines after one, two and three doses in Filipino children. Vaccine. 1998;16:1004–1008
  61. Eskola J, Peltola H, Takala AH, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diptheria toxoid conjugate vaccine in infancy. N Engl J Med. 1987;317:717–722
  62. Kilpi TM, Silfverdal SA, Nilsson L, et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus- Haemophilus influenzae type b vaccines administered at 3, 5 and 11–12 months of age. Hum Vaccin. 2009;5:18–25
  63. Sow SO, Tapiua MD, Diallo S, et al. Haemophilus influenzae type b conjugate vaccine introduction in Mali: impact on disease burden and serologic correlates of protection. Am J Trop Med Hyg. 2009;80:1033–1038
  64. Clemens J, Jodar L. Hi b vaccines for all the world's children?. Lancet. 2005;366:101–103
  65. Johnson NG, Ruggeberg JU, Balfour GF, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis. 2006;12:937–941
  66. Baggett HC, Hennessy TW, Bulkow L, et al. Immunologic response to Haemophilus influenzae type b (Hi b) conjugate vaccine and risk factors for carriage among Hi b carriers and noncarriers in Southwestern Alaska. Clin Vaccine Immunol. 2006;13:620–626
  67. Dentinger CM, Hennessy TW, Bulkow LR, et al. Immunogenicity and reactogenicity to Haemophilus influenzae type b (Hi b) conjugate vaccine among rural Alaska natives. Hum Vaccin. 2006;2:24–28
  68. Feeney AJ, Atkinson MJ, Cowan MJ, et al. A defective VkA2 allele in Navajos which may play a role in increased susceptibility to H. influenzae type b disease. J Clin Invest. 1996;97:2277–2282
  69. Kwiatkowski D. Science, medicine, and the future: susceptibility to infection. Br Med J. 2000;321:1061–1065
  70. Menzies R, McIntyre P. Vaccine preventable diseases and vaccination policy for indigenous populations. Epidemiol Rev. 2006;28:71–80
  71. Asturias EJ, Mayorga C, Caffaro C, et al. Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status. Vaccine. 2009;27:3650–3654
  72. Auranen K, Eichner M, Leino T, et al. Modelling transmission, immunity and disease of Haemophilus influenzae type b in a structured population. Epidemiol Infect. 2004;132:947–957
  73. Agbarakwe AE, Griffiths H, Begg N, et al. Avidity of specific IgG antibodies elicited by immunisation against Haemophilus influenzae type b. J Clin Pathol. 1995;48:206–209
  74. Poolman J, Kaufhold A, De Grave D, et al. Clinical relevance of lower Hi b response in DTPa-based combination vaccines. Vaccine. 2001;19:2280–2285
  75. Romero-Steiner S, Fernandez J, Biltoft C, et al. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate–tetanus toxoid conjugate). Clin Diagn Lab Immunol. 2001;8:1115–1119
  76. Singleton R, Hammitt L, Hennessy T, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics. 2006;118:e421–e429
  77. Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis. 2008;46:186–192
  78. Kelly DF, Moxon ER, Yu LM, et al. Anti-polyribosyl-ribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of Infants in the United Kingdom. Clin Vaccine Immunol. 2009;16:246–252

PII: S0188-4409(10)00136-0

doi: 10.1016/j.arcmed.2010.05.010

Archives of Medical Research
Volume 41, Issue 4 , Pages 281-287 , May 2010

Article Tools

* Image Usage & Resolution